Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.
Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.
Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.
Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.
Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.
A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.
For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.
Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.
Two headgear items, a system of applying electromagnetic currents to patients with glioblastoma and a cooling cap for individuals undergoing chemotherapy for breast cancer, are early entries in the field.
David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.